

## **A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine (IMGN901) in Combination with Carboplatin/Etoposide in Patients with ..**

### **Name**

ImmunoGen Incorporated

### **Anticipated Amount**

446 137.00

### **Activity Type**

Clinical Trial

### **Award Type**

Contract

### **Date**

December 6, 2011 to December 8, 2014

### **Award Number**

005262-00001

### **Sponsor Award Number**

IMGN901

### **Award Contacts**

#### **Name**

Garland,Linda L

#### **Title**

Principal Investigator

#### **Unit**

Cancer Center Division

---

**Source URL:** <https://uaatwork.arizona.edu/grant/phase-12-study-assess-safety-and-efficacy-lorvotuzumab-mertansine-imgn901-combination>